



Envisioning a Transformed Clinical Trials Enterprise for 2030 A Virtual Workshop

March 24 Breakout Discussion Guide – Session 2

Overview

On January 26, February 9, March 24, and May 11, 2021 the National Academies Forum on Drug Discovery, Development, and Translation will host a 4-part virtual workshop on *Envisioning a Transformed Clinical Trials Enterprise for 2030*. Workshop participants will consider lessons learned from progress and setbacks over the past 10 years, and, looking forward, discuss goals and key priorities for advancing a clinical trials enterprise that is more efficient, effective, person-centered, inclusive, and integrated into the health delivery system of 2030. The workshop planning committee has identified three topic-specific priorities for framing the workshop discussions: 1) Enhancing Outcomes in a More Person-Centered and Inclusive Clinical Trials Enterprise; 2) Building a More Resilient, Sustainable, and Transparent Clinical Trials Enterprise; and 3) Practical Applications for Technology to Enhance the Clinical Trials Enterprise.

Breakout group participants will discuss each of the topic-specific priorities listed above.

Discussion Questions for Session 2 of Building a More Resilient, Sustainable, and Transparent Clinical Trials Enterprise

1. What are 1-2 long-term, tangible and measurable goals to ensure a more resilient, sustainable, and transparent clinical trials enterprise that should be met within the next 10 years – by 2030?

Goals to consider:

- *Establish a nation-wide community-based clinical trial network that meets current unmet needs and has the capacity to respond to public health emergencies.*
- *Reimagine career paths for academics and clinicians as clinical trials become more decentralized.*
- *Other long-term goals to ensure a more resilient, sustainable, and transparent clinical trials enterprise?*

2. What technologies, tools, or techniques could be transformational to improving resilience, sustainability, and transparency in the clinical trials enterprise over the next 10 years?

Ideas to consider:

- *Embed clinical trials within the community sites where patients receive care.*
- *Build upon the existing infrastructure of electronic health records to move toward a functional clinical trial network.*

3. What are specific models of sustainability, resilience, or transparency that participants have encountered in the past year that might be informative for the clinical trials enterprise, and could they be scaled (in part or in whole)?